Agent for glandular epithelial-squamous metaplasia transdifferentiation in cancer tissue
An agent targeting FOXQ1 in cancer tissues addresses the molecular interaction between CAFs and cancer cells, promoting or inhibiting metaplastic differentiation to control cancer invasiveness and metastasis.
Patent Information
- Application Number
- JP2023084327
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-05-23
- Publication Date
- 2024-12-05
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The molecular mechanism of how cancer-associated fibroblasts (CAFs) promote cancer cell proliferation, invasion, and metastasis is not well understood, and existing treatments lack effective agents to target this interaction.
Development of an agent containing FOXQ1 or its inducer to promote glandular epithelial-squamous metaplastic differentiation, and an inhibitor to suppress this differentiation, using FOXQ1 inhibitors to target cancer tissues and reduce invasiveness and metastasis.
The agent promotes or suppresses glandular epithelial-squamous metaplastic differentiation in cancer tissues, effectively reducing cancer tissue invasiveness and metastasis by targeting FOXQ1 expression levels.
Smart Images

Figure 2024167978000001 
Figure 2024167978000002 
Figure 2024167978000003
Abstract
Description
[Technical field]
[0001] The present invention relates to an agent for transdifferentiation of cancer tissue from glandular epithelium to squamous epithelium. [Background technology]
[0002] In malignant tumors, not only cancer cells but also many non-cancerous stromal cells exist, forming a cancer microenvironment. Fibroblasts that are abundant in tumors are called carcinoma-associated fibroblasts (CAFs), and are thought to promote the proliferation, invasion, metastasis, and anticancer drug resistance of interacting cancer cells (Non-Patent Document 1), but the molecular mechanisms underlying this are still poorly understood. [Prior art documents] [Patent documents]
[0003] [Non-Patent Document 1] Matsumura Y et al.,Life Science Alliance,2019 Summary of the Invention [Problem to be solved by the invention]
[0004] The objective of the present invention is to provide a new factor involved in the proliferation, invasion, metastasis, etc. of cancer cells through the interaction between CAFs and cancer cells. [Means for solving the problem]
[0005] The present inventors co-transplanted low-invasive / metastatic human breast cancer cells (DCIS) with CAFs into mice and investigated the mechanism of hyperinfection of highly metastatic cancer cells (DCIS CAF2cy This DCIS was established (Non-Patent Document 1). CAF2cyMicroarray analysis of CAFs revealed many genes that are induced in breast cancer by interaction with CAFs. We then investigated the effects of these genes on the interaction between CAFs and DCIS, and found that FOXQ1, the only transcriptional regulator among these genes, promotes glandular epithelial-squamous metaplasia-like transdifferentiation in DCIS that interacts with CAFs, thereby promoting the invasiveness and metastasis of DCIS. CAF2cy Knockdown of FOXQ1 in DCIS suppresses glandular-squamous metaplasia transdifferentiation and results in CAF2cy They found that metastasis to the lungs was suppressed.
[0006] That is, the present invention provides the following inventions [1] to [7]. [1] An agent for promoting the transdifferentiation of glandular epithelium to squamous epithelium in cancer tissue, the active ingredient of which is FOXQ1 or a FOXQ1 inducer. [2] An inhibitor of glandular epithelial-squamous metaplasia transdifferentiation in cancer tissue, containing a FOXQ1 inhibitor as its active ingredient. [3] An agent that suppresses the invasiveness and metastasis of cancer tissue, containing a FOXQ1 inhibitor as its active ingredient. [4] A method for measuring glandular epithelial-squamous metaplasia transdifferentiation in cancer tissue, comprising measuring the expression level of FOXQ1 in the cancer tissue. [5] A method for measuring the invasiveness and metastasis of cancer tissue, comprising measuring the expression level of FOXQ1 in the cancer tissue. [6] A method for screening for a promoter or inhibitor of glandular epithelial-squamous metaplasia transdifferentiation in cancer tissue, comprising measuring the expression level of FOXQ1 in cancer tissue to which a test substance has been added or administered. [7] A method for screening for promoters or inhibitors of invasiveness or metastasis of cancer tissue, comprising measuring the expression level of FOXQ1 in cancer tissue to which a test substance has been added or administered. Effect of the Invention
[0007] The use of FOXQ1 or a FOXQ1 inducer promotes glandular epithelial-squamous metaplastic transdifferentiation in cancer tissue. The use of a FOXQ1 inhibitor inhibits glandular epithelial-squamous metaplastic transdifferentiation in cancer tissue. Furthermore, by measuring the expression level of FOXQ1 in cancer tissue, it is possible to determine whether glandular epithelial-squamous metaplastic transdifferentiation in cancer tissue is promoted or inhibited. By measuring the expression level of FOXQ1 in cancer tissue to which a test substance has been added or administered, it is possible to screen for promoters or inhibitors of glandular epithelial-squamous metaplastic transdifferentiation in cancer tissue. In cancer tissues of epithelial cells, CAFs coexist and interact with cancer cells. Therefore, the agent for inhibiting glandular epithelial-squamous metaplasia transdifferentiation of cancer tissues obtained by the present invention is useful as an agent for inhibiting the invasiveness and metastasis of cancer tissues. [Brief description of the drawings]
[0008] [Figure 1] The results of single-cell analysis of DCIScnt and DCISCAF are shown. The left side shows how the gene transcription dynamics of individual cells constituting DCIScnt and DCISCAF are dimensionally compressed onto a feature space, and how each group of cells forms a cluster in the vicinity. The right side shows the transcriptional activity strength of FOXQ1 estimated from the target genes for each individual cell. [Diagram 2] Figure 2 shows induction of genes (markers) characteristic of glandular metaplasia in DCIS that overexpress FOXQ1. [Diagram 3] Figure 2 shows induction of genes (markers) characteristic of squamous metaplasia in DCIS that overexpress FOXQ1. [Figure 4] FIG. 1 is a schematic diagram showing the three-dimensional tumor invasion assay method. [Diagram 5] Western blot of FOXQ1 and alpha-tubulin using proteins extracted from DCIS into which a construct that induces FOXQ1 expression in a doxycycline-dependent manner was introduced. [Figure 6] We show that DCIS in which FOXQ1 expression was induced in a doxycycline-dependent manner promotes invasion into gels containing extracellular matrix. [Figure 7]Decreased mRNA expression levels of genes (markers) characteristic of glandular metaplasia in DCISCAF2cy with FOXQ1 knockdown. [Figure 8] Decreased mRNA expression levels of genes (markers) characteristic of squamous metaplasia in DCISCAF2cy with FOXQ1 knockdown. [Figure 9] Lung metastasis in mice injected with DCIScnt2cy or DCISCAF2cy via the tail vein is shown. Compared to the control GFP knockdown, DCISCAF2cy with FOXQ1 knockdown suppressed lung metastasis. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0009] One aspect of the present invention is an agent for promoting glandular epithelial-squamous metaplasia transdifferentiation of cancer tissue, which comprises FOXQ1 or a FOXQ1 inducer as an active ingredient. Another aspect of the present invention is an agent for suppressing glandular epithelial-squamous metaplasia transdifferentiation in cancer tissue, which comprises a FOXQ1 inhibitor as an active ingredient. Another aspect of the present invention is an agent for suppressing the invasiveness and metastasis of cancer tissue, which comprises a FOXQ1 inhibitor as an active ingredient.
[0010] FOXQ1 is a member of the FOX protein family of transcription factors that play an important role in regulating the expression of genes involved in cell growth, proliferation, differentiation, and longevity. It is completely unknown what effect the FOXQ1 gene has on cancer cells that coexist with CAFs. As described above, the present inventors found that cancer cells that became highly metastatic after co-transplantation with CAFs, i.e., cancer cells that interacted with CAFs, highly expressed FOXQ1, and that the cancer tissue promoted glandular epithelial-squamous metaplastic transdifferentiation, thereby promoting the invasiveness and metastasis of the cancer tissue. Furthermore, they found that knocking down FOXQ1 in the cancer tissue inhibited glandular epithelial-squamous metaplastic transdifferentiation, thereby inhibiting, for example, metastasis of breast cancer tissue to the lung. Therefore, FOXQ1 or FOXQ1 inducers are useful as agents for promoting glandular epithelial-squamous metaplasia transdifferentiation in cancer tissues. In addition, FOXQ1 inhibitors are useful as agents for suppressing glandular epithelial-squamous metaplasia transdifferentiation in cancer tissues. Furthermore, FOXQ1 inhibitors are useful as agents for suppressing the invasiveness and metastasis of cancer tissues.
[0011] The FOXQ1 used may be a FOXQ1 protein or a FOXQ1 gene. Human FOXQ1 protein and FOXQ1 gene are already known and can be easily obtained by recombinant gene technology. The FOXQ1 inducer may be any component that induces the FOXQ1 protein, and may be the FOXQ1 gene or a vector containing the FOXQ1 gene. The FOXQ1 inhibitor may be any component that has the function of inhibiting the action of the FOXQ1 protein, and examples thereof include anti-FOXQ1 antibodies, FOXQ1 gene expression inhibitors, and FOXQ1 protein stability inhibitors.
[0012] The cancer tissues targeted by the present invention may be any cancer tissue in which CAFs coexist, and specific examples thereof include epithelial cancers (respiratory cancer, digestive cancer, urogenital cancer, endocrine cancer, skin cancer, etc.), mesothelioma, breast cancer, sarcoma, central nervous system tumors, peripheral nervous system tumors, etc. Respiratory cancers include lung cancer (non-small cell lung cancer, small cell lung cancer, etc.). Digestive cancers include esophageal cancer, gastric cancer, duodenal cancer, liver cancer, biliary tract cancer (gallbladder / bile duct cancer, etc.), pancreatic cancer, colon cancer, colorectal cancer (colon cancer, rectal cancer, etc.). Urogenital cancers include ovarian cancer, uterine cancer (cervical cancer, uterine body cancer, etc.), kidney cancer, bladder cancer, prostate cancer, testicular tumors, etc. Endocrine cancers include neuroendocrine tumors, etc. Examples of mesothelioma include pleural mesothelioma, peritoneal mesothelioma, pericardial mesothelioma, and testicular mesothelioma. Examples of sarcoma include gastrointestinal stromal tumor, bone and soft tissue tumor, etc. Examples of central nervous system tumor include brain tumor, etc. Examples of peripheral nervous system tumor include malignant nerve sheath tumor, etc. Among these, preferred are gastrointestinal stromal tumor, breast cancer, lung cancer, gastric cancer, prostate cancer, ovarian cancer, and colon cancer, and among lung cancer, non-small cell lung cancer is preferred.
[0013] In the present invention, glandular epithelium-squamous metaplasia transdifferentiation refers to the differentiation of an epithelial tumor component of cancer (adenocarcinoma) into squamous epithelium. Keratinization or intercellular bridges are observed in cancer nests, and they are often mixed with adenocarcinoma components. It is known that the occurrence of squamous metaplasia generally leads to high malignancy, such as rapid growth and metastasis, and poor prognosis for chemotherapy. Therefore, when glandular epithelium-squamous metaplasia transdifferentiation is promoted in cancer tissue, the cancer tissue becomes more invasive and metastatic. That is, FOXQ1 inhibitors are useful as medicines for inhibiting glandular epithelial-squamous metaplasia transdifferentiation in cancer tissues, and further, FOXQ1 inhibitors are useful as medicines for inhibiting the invasiveness and metastasis of cancer tissues.
[0014] The administration route of the pharmaceutical of the present invention is not particularly limited, and it can be administered orally or parenterally. Parenteral administration includes intravenous, intramuscular, subcutaneous or intradermal injection, inhalation, rectal administration, intranasal administration, topical administration, etc. The medicine of the present invention may be administered to a patient as an active ingredient, the FOXQ1 inhibitor, but should preferably be administered in the form of a pharmaceutical composition containing the active ingredient and a pharmaceutical acceptable additive. Examples of the pharmaceutical acceptable additive include excipients, disintegrants or disintegration aids, binders, lubricants, coating agents, dyes, diluents, bases, solubilizers or solubilizers, isotonicity agents, pH regulators, stabilizers, propellants, and adhesives.
[0015] Examples of formulations suitable for oral administration include tablets, capsules, powders, fine granules, granules, liquids, and syrups, while examples of formulations suitable for parenteral administration include injections, drips, suppositories, inhalants, and topical preparations (including patches, ointments, creams, gels, lotions, sprays, and the like). Preparations suitable for oral administration may contain, as additives, excipients such as glucose, lactose, D-mannitol, starch, or crystalline cellulose; disintegrants or disintegration aids such as carboxymethylcellulose, starch, or carboxymethylcellulose calcium; binders such as hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, or gelatin; lubricants such as magnesium stearate or talc; coating agents such as hydroxypropylmethylcellulose, sucrose, polyethylene glycol, or titanium oxide; and bases such as petrolatum, liquid paraffin, polyethylene glycol, gelatin, kaolin, glycerin, purified water, or hard fat. Preparations suitable for injection or infusion may contain additives for formulations, such as dissolving agents or solubilizing aids capable of constituting aqueous or ready-to-use injections, such as distilled water for injection, physiological saline, propylene glycol, etc.; isotonicity agents, such as glucose, sodium chloride, D-mannitol, glycerin, etc.; and pH adjusters, such as inorganic acids, organic acids, inorganic bases, or organic bases. Preparations suitable for suppositories can use, for example, bases such as polyethylene glycol, lanolin, cacao butter, fatty acid triglycerides, and, if necessary, additives such as surfactants, such as nonionic surfactants. Preparations suitable for ointments may contain commonly used bases, stabilizers, wetting agents, preservatives, etc. as necessary. Examples of bases include liquid paraffin, white petrolatum, white beeswax, octyldodecyl alcohol, paraffin, etc. Examples of preservatives include methyl parahydroxybenzoate, ethyl parahydroxybenzoate, propyl parahydroxybenzoate, etc. Preparations suitable for use as patches include those prepared by applying the above-mentioned ointments, creams, gels, pastes, etc., to a common support in a conventional manner. Suitable supports include woven or nonwoven fabrics made of cotton, staple fiber, or chemical fibers, and films or foam sheets made of soft polyvinyl chloride, polyethylene, polyurethane, etc.
[0016] The medicament of the present invention is also useful in combination with other anticancer drugs that act directly on cancer cells. Such other anticancer drugs that can be used in combination are not particularly limited as long as they have an anticancer effect, but it is particularly preferable that the other anticancer drugs have tumor cell cytotoxicity in terms of obtaining a synergistic effect. Such other anticancer agents include alkylating agents, metabolic antagonists, microtubule inhibitors, antibiotic anticancer agents, topoisomerase inhibitors, platinum agents, molecular targeted drugs, hormone agents, and biological agents. Examples of alkylating agents include cyclophosphamide, ifosfamide, nitrosourea, dacarbazine, temozolomide, nimustine, busulfan, melphalan, procarbazine, and ranimustine. Examples of metabolic antagonists include enocitabine, carmofur, capecitabine, tegafur, tegafur-uracil, tegafur-gimeracil-oteracil potassium, gemcitabine, cytarabine, cytarabine ocfosfate, nelarabine, fluorouracil, fludarabine, pemetrexed, pentostatin, methotrexate, cladribine, doxifluridine, hydroxycarbamide, and mercaptopurine. Examples of microtubule inhibitors include alkaloid anticancer agents such as vincristine, and taxane anticancer agents such as docetaxel and paclitaxel. Examples of antibiotic anticancer agents include mitomycin C, doxorubicin, epirubicin, daunorubicin, bleomycin, actinomycin D, aclarubicin, idarubicin, pirarubicin, peplomycin, mitoxantrone, amrubicin, zinostatin stimalamer, and the like. Examples of topoisomerase inhibitors include CPT-11, irinotecan, and nogitecan, which have a topoisomerase I inhibitory effect, and etoposide and sobuzoxane, which have a topoisomerase II inhibitory effect. Examples of platinum agents include cisplatin, nedaplatin, oxaliplatin, carboplatin, and the like. Examples of hormone drugs include dexamethasone, finasteride, tamoxifen, astrozole, exemestane, ethinyl estradiol, chlormadinone, goserelin, bicalutamide, flutamide, prednisolone, leuprorelin, letrozole, estramustine, toremifene, fosfestrol, mitotane, methyltestosterone, medroxyprogesterone, and mepitiostane. Examples of biological agents include interferon α, β and γ, interleukin 2, ubenimex, and dried BCG. Examples of molecular targeted drugs include rituximab, alemtuzumab, trastuzumab, cetuximab, panitumumab, imatinib, dasatinib, nilotinib, gefitinib, erlotinib, temsirolimus, bevacizumab, VEGF trap, sunitinib, sorafenib, tosituzumab, bortezomib, gemtuzumab ozogamicin, ibritumomab ozogamicin, ibritumomab tiuxetan, tamibarotene, and tretinoin. Furthermore, inhibitors targeting angiogenesis, such as human epidermal growth factor receptor 2 inhibitors, epidermal growth factor receptor inhibitors, Bcr-Abl tyrosine kinase inhibitors, epidermal growth factor tyrosine kinase inhibitors, mTOR inhibitors, vascular endothelial growth factor receptor 2 inhibitors (α-VEGFR-2 antibodies), various tyrosine kinase inhibitors such as MAP kinase inhibitors, inhibitors targeting cytokines, proteasome inhibitors, and molecular targeted drugs, such as antibody-anticancer drug combinations, can also be used. Among these other anticancer drugs, alkylating agents characterized by cytotoxic activity, metabolic antagonists, microtubule inhibitors, antibiotic anticancer drugs, topoisomerase inhibitors, platinum preparations, molecular targeted drugs, etc. are particularly preferred. Specifically, gemcitabine, 5-FU, CPT-11, etoposide, cisplatin, oxaliplatin, paclitaxel, docetaxel, dacarbazine, doxorubicin, bevacizumab, cetuximab, anti-vascular endothelial growth factor receptor 2 inhibitory antibodies, epidermal growth factor tyrosine kinase inhibitors, etc. are particularly preferred.
[0017] The dosage of the pharmaceutical of the present invention can be appropriately selected depending on various conditions such as the progression of the disease or the severity of the symptoms, and the age and body weight of the patient. For example, in the case of oral administration, 1 mg to 300 mg per day can be administered in one to three divided doses.
[0018] Another aspect of the present invention is a method for measuring glandular epithelial-squamous metaplasia transdifferentiation of cancer tissue, which comprises measuring the expression level of FOXQ1 in the cancer tissue. Another aspect of the present invention is a method for measuring the invasiveness and metastasis of cancer tissue, which comprises measuring the expression level of FOXQ1 in the cancer tissue. According to the present invention, the expression level of FOXQ1 in cancer tissue is measured, and if the expression level is higher than that of healthy subjects or other cancer patients, it can be determined that the cancer tissue has a high degree of glandular epithelial-squamous metaplasia transdifferentiation and that the cancer tissue has a high degree of invasiveness and metastatic potential. The subject of measurement is the cancer tissue of the subject. The FOXQ1 expression level is measured by preparing paraffin-embedded tissue blocks from cancer tissue samples taken from histological examinations or surgical specimens, thinly slicing them to prepare tissue sections, and detecting them by tissue staining with FOXQ1 antibodies. Alternatively, mRNA is extracted from cancer tissue samples taken from histological examinations or surgical specimens, and the FOXQ1 expression level is measured by quantitative PCR. The expression level of FOXQ1 can be determined using the expression level of a healthy subject or the expression level of a cancer patient who has not developed metastasis or the like as a control.
[0019] Another aspect of the present invention is a screening method for promoters or inhibitors of glandular epithelial-squamous metaplasia transdifferentiation in cancer tissue, characterized by measuring the level of FOXQ1 expression in cancer tissue to which a test substance has been added or administered. Another aspect of the present invention is a method for screening for promoters or suppressors of invasiveness and metastasis of cancer tissue, which comprises measuring the expression level of FOXQ1 in cancer tissue to which a test substance has been added or administered. According to the present invention, by measuring the expression level of FOXQ1 in cancer tissue to which a test substance has been added or administered, and comparing the expression level with that when the test substance is not administered, it is possible to screen for promoters or inhibitors of glandular epithelial-squamous metaplasia transformation in cancer tissue, and promoters or inhibitors of the invasiveness and metastasis of cancer tissue. The cancer tissue used in the test may be any cancer tissue in which cancer cells and CAFs coexist, and may be, for example, the cancer tissues described above. The means for measuring the FOXQ1 expression level are the same as those described above. EXAMPLES
[0020] Next, the present invention will be described in more detail with reference to examples, but the present invention is not limited to these examples.
[0021] Example 1 (Highly metastatic DCIS cancer cells CAF2cy Establishment of We mixed low-invasive / metastatic human breast cancer cells (DCIS) and CAFs and transplanted them into immunodeficient mice. The tumors that formed were excised and recultured.CAF1cy DCIS was established. CAF1cy The mice were then transplanted with CAFs into immunodeficient mice, and the tumors that formed were excised and recultured to produce highly metastatic DCIS cancer cells. CAF2cy As a control, DCIS was co-transplanted with fibroblasts. cnt1cy ,DCIS cnt2cy was established (Non-patent Document 1). (Method and results of microarray analysis) DCIS and CAFs were co-transplanted into mice twice, and the tumors formed from DCIS were CAF2cy DCIS was established four times independently, and DCIS was also established from the co-implantation of DCIS and control fibroblasts. cnt2cy Four types of DCIS were established independently four times. CAF2cy and four types of DCIS cnt2cy mRNA was extracted from each of the DCIS and gene expression analysis was performed using GeneChip Human Genome U133 Plus 2.0 Arrays (Affymetrix) (Non-Patent Document 1). cnt2cy In the sarcolemma, the expression of the transcription factor FOXQ1, the squamous epithelium-specific genes SCEL, SERPINB1, SERPINB2, SERPINB3, SPRR1A, SPRR3, and TGM2, and the glandular epithelium-specific genes CEACAM5 and CEACAM6 were induced.
[0022] Example 2 (DCIS cnt and DCIS CAF Single-cell analysis of (method) DCIS cells were transplanted once or twice into mice with CAFs (DCIS CAF1cy , DCIS CAF2cy ) and DCIS co-implanted with control fibroblasts (DCIS cnt1cy , DCIS cnt2cyWe analyzed the transcriptional dynamics of the four groups by single cell assay for transposase-accessible chromatin (ATAC)-seq. Samples were prepared from individual cells from the four groups using the SureCell ATAC-seq library preparation kit (BioRad), and the open chromatin regions were comprehensively sequenced using a next-generation sequencer. (result) As shown in Figure 1, FOXQ1 is a novel marker for DCIS. CAF2cy The gene transcription dynamics was compressed onto the feature space, and the DCIS CAF1cy , DCIS CAF2cy , DCIS cnt1cy , DCIS cnt2cy The individual cells that constituted DCIS formed clusters. The transcriptional activity of FOXQ1 estimated from the target genes was cnt1cy Clusters were the lowest, DCIS CAF2cy It was the highest in the cluster.
[0023] Example 3 (Induction of gene expression by overexpression of FOXQ1) (method) FOXQ1 or a control GFP was overexpressed in DCIS cells by lentivirus-mediated gene transfer. mRNA was extracted from stable GFP or FOXQ1 expressing cells and reverse transcribed into cDNA. The expression levels of each gene were analyzed by quantitative PCR. (result) As shown in Figures 2 and 3, in DCIS that overexpressed FOXQ1, the expression of mRNA of a group of genes characteristic of glandular epithelium-squamous metaplasia was induced.
[0024] Example 3 (Overexpression of FOXQ1 enhances invasiveness) (method) DCIS was layered on an extracellular matrix gel (a mixture of Matrigel and type I collagen) containing normal fibroblasts and cultured for 12 days. After that, the sections were embedded in paraffin and thinly cut, and stained with hematoxylin and eosin to observe cancer cell invasion into the extracellular matrix layer (Figure 4). (result) Figure 5 shows the results of Western blot detection of FOXQ1 protein induction in DCIS that overexpress FOXQ1 in a doxycycline-dependent manner. Doxycycline was added to the culture medium at a concentration of 10 to 1000 ng / ml, and the total intracellular protein was collected after 24 hours of culture. Figure 6 shows the enhanced invasion into the extracellular matrix layer of DCIS cultured for 12 days with the addition of 1 μg / ml doxycycline. These results show that DCIS that overexpress FOXQ1 in a doxycycline-dependent manner have enhanced invasive ability.
[0025] Example 4 (Changes in gene expression due to FOXQ1 knockdown) (method) Two shRNAs targeting FOXQ1 or a control shRNA targeting GFP were delivered to DCIS cells by lentivirus-mediated gene transfer. cnt2cy mRNA was extracted from the cells in which GFP or FOXQ1 was knocked down, and reverse transcribed into cDNA. The expression levels of various genes were then analyzed by quantitative PCR. (result) Knocking down FOXQ1 in DCISCAF2cy suppressed the expression of mRNA for a group of genes characteristic of glandular-squamous metaplasia (Fig. 7, Fig. 8).
[0026] Example 5 (DCIS CAF2cy Contribution of FOXQ1 to lung metastasis of breast cancer (method) Control DCIS with GFP knockdown cnt2cy GFP knockdown DCIS CAF2cy , and two types of FOXQ1 knockdown DCIS CAF2cy Each was injected into the tail vein of a mouse, and 30 days later, the mouse was excised and observed under a stereomicroscope. (result) DCIS with FOXQ1 knockdown CAF2cy suppressed metastasis to the lungs compared with control GFP knockdown (Figure 9).
Claims
1. An agent for promoting glandular epithelium-squamous metaplasia transdifferentiation of cancer tissue, comprising FOXQ1 or a FOXQ1 inducer as an active ingredient.
2. An inhibitor of glandular epithelium-squamous metaplasia transdifferentiation in cancer tissue, comprising a FOXQ1 inhibitor as an active ingredient.
3. An agent for suppressing the invasiveness and metastasis of cancer tissue, the agent comprising a FOXQ1 inhibitor as an active ingredient.
4. A method for measuring glandular epithelial-squamous metaplasia transdifferentiation of cancer tissue, comprising measuring the amount of FOXQ1 expression in the cancer tissue.
5. A method for measuring the invasiveness and metastasis of cancer tissue, comprising measuring the expression level of FOXQ1 in the cancer tissue.
6. A screening method for a promoter or inhibitor of glandular epithelial-squamous metaplasia transdifferentiation in cancer tissue, comprising measuring the expression level of FOXQ1 in cancer tissue to which a test substance has been added or administered.
7. A method for screening for a promoter or suppressor of the invasiveness or metastasis of cancer tissue, comprising measuring the expression level of FOXQ1 in cancer tissue to which a test substance has been added or administered.
